YC W20
Isabl
Cancer tests based on whole genome and transcriptome data.
About
Isabl has developed software that can analyze the entire genome of cancer patients. Today, when people get cancer, they get a genetic test of their tumor that analyzes only a few possible mutations. With Isabl, you run the tumor through an Illumina sequencer and get the whole genome, then our software is able to analyze all the mutations. Our breakthrough technology provides unprecedented clarity into tumor biology to aid treatment planning. This opens up opportunities for precision diagnostics, disease surveillance and biomarker discovery.
Founders
- Andrew Kung
- Elli Papaemmanuil
Family Office Investors
1 deal trackedAltss has tracked family office activity in Isabl. Investors shown are from our private markets database.
- Milad Alucozai (Angel)
Industry & Focus
HealthcareDiagnosticsBiotech